CDK 4/6 Inhibitor Combos Could Have Lasting Benefits in ER+ Metastatic Breast Cancer

Jason Harris
Published: Tuesday, Aug 27, 2019
Dr Angela M. DeMichele

Angela M. DeMichele, MD

Although CDK4/6 inhibitors are remaking the treatment landscape for patients with estrogen receptor (ER)–positive metastatic breast cancer, questions about optimal sequencing and strategies for attacking resistance and progression remain unsettled, according to Angela DeMichele, MD, MSCE.

Table. CDK 4/6 Inhibitor Efficacy by Line of Therapy1

Table. CDK 4/6 Inhibitor Efficacy by Line of Therapy1 In MONARCH 2, 669 women with HR-positive, HER2-negative advanced breast cancer resistant to endocrine therapy were assigned to abemaciclib plus fulvestrant or to placebo and fulvestrant. At a median follow-up of 19.5 months, the median PFS with the combination was 16.4 months compared to 9.3 months with placebo (hazard ratio, 0.553; P <.001). The objective response rates were 48.1% vs 21.3%, respectively.4
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication